Oxybutynin Patent Expiration
Oxybutynin is Used for treating overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence. It was first introduced by Allergan Sales Llc
Oxybutynin Patents
Given below is the list of patents protecting Oxybutynin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Gelnique 3% | US7198801 | Formulations for transdermal or transmucosal application |
Jun 25, 2022
(Expired) | Allergan |
| Gelnique 3% | US7029694 | Compositions and methods for transdermal oxybutynin therapy |
Apr 26, 2020
(Expired) | Allergan |
| Gelnique 3% | US7179483 | Compositions and methods for transdermal oxybutynin therapy |
Apr 26, 2020
(Expired) | Allergan |
| Gelnique 3% | US8241662 | Unoccluded topical oxybutynin gel composition and methods for transdermal oxybutynin therapy |
Apr 26, 2020
(Expired) | Allergan |
| Oxytrol | US6743441 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr 26, 2020
(Expired) | Allergan |
| Oxytrol | US7081249 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr 26, 2020
(Expired) | Allergan |
| Oxytrol | US7081250 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr 26, 2020
(Expired) | Allergan |
| Oxytrol | US7081251 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr 26, 2020
(Expired) | Allergan |
| Oxytrol | US7081252 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr 26, 2020
(Expired) | Allergan |
| Oxytrol | US7179483 | Compositions and methods for transdermal oxybutynin therapy |
Apr 26, 2020
(Expired) | Allergan |
| Oxytrol For Women | US6743441 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr 26, 2020
(Expired) | Abbvie |
| Oxytrol For Women | US7081249 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr 26, 2020
(Expired) | Abbvie |
| Oxytrol For Women | US7081250 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr 26, 2020
(Expired) | Abbvie |
| Oxytrol For Women | US7081251 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr 26, 2020
(Expired) | Abbvie |
| Oxytrol For Women | US7081252 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr 26, 2020
(Expired) | Abbvie |
| Oxytrol For Women | US7179483 | Compositions and methods for transdermal oxybutynin therapy |
Apr 26, 2020
(Expired) | Abbvie |
| Oxytrol | US5601839 | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
Apr 26, 2015
(Expired) | Allergan |
| Oxytrol | US5834010 | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
Apr 26, 2015
(Expired) | Allergan |
| Oxytrol For Women | US5601839 | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
Apr 26, 2015
(Expired) | Abbvie |
| Oxytrol For Women | US5834010 | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
Apr 26, 2015
(Expired) | Abbvie |
Oxybutynin's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Oxybutynin:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Parallel Arm Trial of AD109 and AD504 In Patients With OSA | Apnimed | NA |
COMPLETED
(Aug 1, 2026)
| PHASE2 |
| Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study) | Apnimed | NA |
COMPLETED
(Aug 1, 2026)
| PHASE3 |
| Atomoxetine and DAW2022 on OSA Severity | Brigham and Women's Hospital | NA |
RECRUITING
(Jul 1, 2026)
| PHASE1, PHASE2 |
| Early Oxybutinin Treatment for Boys With Posterior Urethral Valves | University Hospital, Bordeaux | NA |
RECRUITING
(Jun 1, 2026)
| PHASE2 |